Compare iShares Core MSCI Emerging Markets ETF (IEMG) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core MSCI Emerging Markets ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? iShares Core MSCI Emerging Markets ETF trades at $81.24 (market cap $162.00B), while Vertex Pharmaceuticals Incorporated trades at $510.07 (market cap $127.55B). The key difference: iShares Core MSCI Emerging Markets ETF is the larger of the two by market cap, and iShares Core MSCI Emerging Markets ETF is more actively traded (13,446,151 versus 1,487,944). Which is the better fit depends on your goals — on Pluang, investors hold iShares Core MSCI Emerging Markets ETF for 57 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| IEMG | VRTX | |
|---|---|---|
Market Cap | $162.00B | $127.55B |
Volume | 13,446,151 | 1,487,944 |
Sector | Broad Market / Factor | Health |
52-Week High | $86.00 | $557.96 |
52-Week Low | $64.22 | $407.37 |
Typical Hold Time | 57 Days | 120 Days |
Enterprise Value | — | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEMG trades at $81.29, down 0.91% with bearish technical signals dominating. The ETF faces selling pressure with moving averages indicating a downtrend, though oscillators remain neutral. Recent news highlights IEMG's strong performance against emerging market peers and its appeal for long-term portfolio strategies despite higher volatility compared to developed market alternatives.
The outlook remains cautious given technical weakness, though emerging market exposure offers growth potential. Key risks include sector concentration in technology and emerging market volatility. Analyst comparisons favor IEMG for cost efficiency and performance, but investors should weigh higher drawdowns against return potential.
Vertex Pharmaceuticals (VRTX) trades at $509.98, up 0.86% today, with a bearish technical signal but strong fundamentals. The company reported $12.00B revenue in 2025 with a 35% net income margin and robust cash flow. Recent positive Phase 2b data for inaxaplin in kidney disease and dominant cystic fibrosis market position support growth. Analysts maintain a strong buy consensus with a $573.50 price target, indicating 12% upside potential.
Outlook remains positive driven by pipeline expansion and high profitability, though risks include clinical trial outcomes and market volatility. The stock's valuation at 29.31 P/E is reasonable for its growth profile, but investor sentiment is cautious near-term due to mixed earnings beats and technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares Core MSCI Emerging Markets ETF
IEMG tracks the MSCI Emerging Markets Investable Market Index, providing broad exposure to large, mid, and small-cap stocks across over 20 emerging market countries. It is designed as a low-cost core holding for investors seeking diversified growth from economies outside of developed markets.
Read more on IEMG →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
